281
Participants
Start Date
January 9, 2019
Primary Completion Date
November 5, 2026
Study Completion Date
November 5, 2026
Fitusiran
Pharmaceutical form:solution for injection Route of administration: subcutaneous
Investigational Site Number : 3720002, Dublin
Investigational Site Number : 3720001, Crumlin
Investigational Site Number : 1580003, Taipei
Investigational Site Number : 1580001, Taipei
Investigational Site Number : 1580005, Taipei
Investigational Site Number : 1580002, Changhua
Investigational Site Number : 3480002, Budapest
Investigational Site Number : 8040003, Kyiv
Investigational Site Number : 0360001, Camperdown
Investigational Site Number : 2080001, Copenhagen
Investigational Site Number : 0360003, Prahran
Investigational Site Number : 4100004, Seoul
Investigational Site Number : 7100002, Port Elizabeth
Investigational Site Number : 0360002, Murdoch
Investigational Site Number : 2760001, Berlin
Investigational Site Number : 3800002, Milan
Investigational Site Number : 7920006, Gaziantep
Nemours Children's Clinic Site Number : 8400008, Jacksonville
Investigational Site Number : 1580007, Taoyuan
St Joseph's Children's Hospital of Tampa Site Number : 8400002, Tampa
Investigational Site Number : 7920005, Istanbul
Investigational Site Number : 7920012, Bornova
Investigational Site Number : 3800004, Padua
Investigational Site Number : 4100002, Daejeon
Investigational Site Number : 7920008, Kayseri
Investigational Site Number : 1580008, Taichung
Investigational Site Number : 1580004, Taichung
Childrens Hospital Medical Center of Akron Site Number : 8400006, Akron
Investigational Site Number : 8040004, Mykolaiv
Investigational Site Number : 7920007, Samsun
Investigational Site Number : 4580003, Ampang
Investigational Site Number : 2500002, Lyon
Investigational Site Number : 2500003, Paris
Investigational Site Number : 8040002, Lviv
Investigational Site Number : 4580001, Johor Bahru
Phoenix Childrens Hospital Site Number : 8400009, Phoenix
Investigational Site Number : 4580002, Kota Kinabalu
Investigational Site Number : 1560005, Hangzhou
Children's Hospital Los Angeles Site Number : 8400019, Los Angeles
Center for Inherited Blood Disorders (CIBD) Site Number : 8400016, Orange
Investigational Site Number : 1560004, Beijing
Investigational Site Number : 1560007, Beijing
Investigational Site Number : 1560003, Shanghai
Investigational Site Number : 1560006, Suzhou
Investigational Site Number : 3560005, Lucknow
Investigational Site Number : 1560008, Jinan
Investigational Site Number : 1560010, Qingdao
Investigational Site Number : 1560014, Changsha
Investigational Site Number : 3560002, Pune
Investigational Site Number : 3560010, Pune
Investigational Site Number : 1560002, Guangzhou
Investigational Site Number : 1560011, Guiyang
Investigational Site Number : 3560001, Bangalore
Investigational Site Number : 1560009, Chengdu
Investigational Site Number : 3560004, Ranipet
Investigational Site Number : 1560012, Kunming
Investigational Site Number : 1560013, Lanzhou
Investigational Site Number : 3920008, Tokyo
Investigational Site Number : 3920005, Isehara
Investigational Site Number : 3920001, Nagoya
Investigational Site Number : 3760001, Ramat Gan
Investigational Site Number : 3920003, Kitakyushu
Rush University Medical Center -1725 W Harrison St Site Number : 8400001, Chicago
~Massachusetts General Hospital Site Number : 8400011, Boston
University of Michigan Hospital - 1500 E Medical Center Dr Site Number : 8400012, Ann Arbor
Alliance for Childhood Diseases Site Number : 8400007, Las Vegas
Investigational Site Number : 1240001, Montreal
Investigational Site Number : 2760003, Leipzig
Investigational Site Number : 3560007, Mumbai
Investigational Site Number : 3920002, Nishinomiya
Investigational Site Number : 3920004, Saitama
Investigational Site Number : 4100001, Busan
Investigational Site Number : 4100003, Seoul
Investigational Site Number : 7920002, Adana
Investigational Site Number : 7920004, Akdeniz
Investigational Site Number : 7920003, Izmir
Investigational Site Number : 8040001, Kyiv
Investigational Site Number : 8260001, London
Investigational Site Number : 8260004, Glasgow
Genzyme, a Sanofi Company
INDUSTRY